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Abstract
Aims: 1-Methyl-4-phenyl-tetrahydropyridine (MPTP) is among the most widely used neurotoxins for inducing
experimental parkinsonism. MPTP causes parkinsonian symptoms in mice, primates, and humans by killing a
subpopulation of dopaminergic neurons. Extrapolations of data obtained using MPTP-based parkinsonism
models to human disease are common; however, the precise mechanism by which MPTP is converted into its
active neurotoxic metabolite, 1-methyl-4-phenyl-pyridinium (MPP+), has not been fully elucidated. In this study,
we aimed to address two unanswered questions related to MPTP toxicology: (1) Why are MPTP-converting
astrocytes largely spared from toxicity? (2) How does MPP+ reach the extracellular space? Results: In MPTP-
treated astrocytes, we discovered that the membrane-impermeable MPP+, which is generally assumed to be
formed inside astrocytes, is almost exclusively detected outside of these cells. Instead of a transporter-mediated
export, we found that the intermediate, 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), and/or its un-
charged conjugate base passively diffused across cell membranes and that MPP+ was formed predominately by
the extracellular oxidation of MPDP+ into MPP+. This nonenzymatic extracellular conversion of MPDP+ was
promoted by O2, a more alkaline pH, and dopamine autoxidation products. Innovation and Conclusion: Our
data indicate that MPTP metabolism is compartmentalized between intracellular and extracellular environments,
explain the absence of toxicity in MPTP-converting astrocytes, and provide a rationale for the preferential
formation of MPP+ in the extracellular space. The mechanism of transporter-independent extracellular MPP+
formation described here indicates that extracellular genesis of MPP+ from MPDP is a necessary prerequisite for
the selective uptake of this toxin by catecholaminergic neurons. Antioxid. Redox Signal. 23, 1001–1016.
Introduction
The experimental study of dopamine (DA) neurondegeneration (a hallmark of Parkinson’s disease) relies
on toxicants that specifically induce pathological states
reminiscent of human parkinsonism by inducing the selective
death of DA neurons. Among the chemical tools currently
used to induce DA neuron degeneration, MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine) most closely reproduces
human parkinsonian pathology in mice and primates (3, 31).
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MPTP is a lipophilic and noncytotoxic prodrug that crosses
the blood–brain barrier and is then converted into the active
toxicant MPP+ (23, 32, 54). Once MPP+ reaches a critical
concentration in the cerebrospinal fluid, it acts as a molecular
‘‘Trojan Horse’’ in DA neurons as a result of its selective
uptake by the dopamine transporter (DAT) (26). Unlike DA,
MPP+ accumulates in mitochondria, where it acts as an in-
hibitor of complex I of the respiratory chain (38) and thereby
kills its host cell (10). However, a vexing enigma pertaining
to the neurotoxic mechanisms of MPTP remains unsolved.
MPTP is converted to MPP+ in astrocytes by the enzyme,
monoamine oxidase-B (MAO-B), which is localized on the
outer mitochondrial membrane of astrocytes (44). How
MPP+ exits astrocytes rather than accumulating in their mi-
tochondria is unknown.
Due to its charge, the active toxicant MPP+ cannot cross
membranes. Recent reports have suggested that passive
transporters, such as the family of organic cation transporters
(OCTs) or the plasma membrane monoamine transporter, are
necessary for MPP+ efflux from astrocytes (9, 37). OCT3 was
observed by Cui et al. to be preferentially expressed in glial
cells in the vicinity of midbrain DA neurons that degenerated
in response to MPTP treatment, and it was hypothesized that
a preferential export of intracellular astrocytic MPP+ via
OCT3 might contribute to the loss of adjacent DA neurons
(9). However, a recent study clearly demonstrated the global
formation of MPP+ in the whole brain only minutes after
MPTP administration and a subsequent rapid clearance from
most regions (28). This indicates that glial cells devoid of
OCT3 expression must also contribute to MPTP conversion
and MPP+ release. Moreover, conventions in membrane bio-
physics suggest that passive transporters such as OCT3 would
contribute to an uptake of MPP+ from the cerebrospinal fluid
into cells (49). A plasma membrane potential of -70 mV
would drive a 15-fold increase in the accumulation of a posi-
tively charged molecule inside cells according to the Nernst
equation. Hence, the presence of OCTs in glial cells would
rather lead to a reduction of extracellular MPP+ and its toxicity
in neurons, as it was observed with monovalent paraquat (42).
MPTP can form several metabolites other than MPP+ in the
brain (52) and their biochemical and physical properties need
to be taken into account to understand the possible mecha-
nisms of MPP+ transport across the membrane. The first
metabolic step in MPP+ formation is always an MAO-
dependent two-electron oxidation yielding the unstable in-
termediate MPDP+ (5). A nonenzymatic autoxidation of
MPDP+ has been suggested as the most likely second step of
MPP+ formation (30). In addition, a disproportionation re-
action yielding one molecule of MPTP and MPP+ from two
molecules of MPDP+ has been described (4, 39). However,
this reaction takes place only at concentrations of MPDP+
(millimolar range) unlikely to occur in biological systems.
The complex chemistry of MPDP+ involves further sponta-
neous reactions; as an a,b-unsaturated iminium ion, MPDP+
can exist in tautomeric forms, and/or in its conjugate base
form, 1,2-MPDP (4, 5). The latter noncharged metabolite is
capable of crossing biological membranes.
In the present work, we report two main findings: (1) the
MAO-catalyzed MPTP intermediate metabolite, MPDP+/
1.2-MPDP, undergoes transporter-independent export from
the cell and (2) MPDP+/1.2-MPDP is responsible for non-
enzymatic MPP+ formation in the extracellular space. These
mechanisms explain why MPTP-converting glial cells are
spared from MPP+ toxicity and how extracellular MPP+ is
generated, which is a necessary prerequisite for the accu-
mulation of MPP+ in catecholaminergic cells.
Results
Extracellular MPP + generation by MPTP-converting
astrocytes predominates
We studied the conversion of MPTP to MPP+ by astrocytes
in the mouse astrocytic cell line, immortalized mouse astro-
cyte (IMA) 2.1, which displays MPTP metabolism properties
comparable with primary astrocytes [Fig. 1A, B (45)]. We
observed an accumulation of the biologically active toxicant
MPP+ in the IMA culture medium, but not within the cells
(Fig. 1C, D). Addition of the OCT3 inhibitor, D22, to the
culture medium had no influence on MPP+ release or uptake
(data not shown), suggesting that the previously suggested
OCT3 transport mechanism (9) was not obligatory for ex-
tracellular MPTP/MPP+ accumulation. However, the MPTP-
converting enzyme, MAO-B, is located exclusively within
the astrocytic cell body, and MPP+, as a charged molecule,
cannot penetrate biological membranes. This raises the fol-
lowing question: How can MPP+ be efficiently generated
extracellularly in the absence of a system for its transport
from the cell (Fig. 1C)?
To resolve this issue, we generated IMA subclones that
stably express OCT3 (a passive transporter of MPP+), DAT
(accumulates MPP+ against a concentration gradient), or both
DAT and OCT3; these cells lines are referred to as OCT3-
IMA, DAT-IMA, and OCT3/DAT-IMA, respectively.
Expression levels of OCT3 in the OCT3-IMA and OCT3/
DAT-IMA lines were identical (Supplementary Fig. S1A;
Supplementary Data are available online at www.liebertpub
.com/ars), and the transport capacity and pharmacological
features were comparable with those of the human kidney
carcinoma cell line, Caki-1, which endogenously expresses
OCT3 (22). We next assessed MPP+ transport in these cell
lines. In DAT-IMAs, uptake of MPP+ was prevented by the
Innovation
The well-studied parkinsonian toxicant, 1-methyl-4-
phenyl-tetrahydropyridine (MPTP), requires astrocytic
metabolism to generate 1-methyl-4-phenyl-pyridinium
(MPP+). Subsequently, MPP+ is transported into dopa-
minergic neurons by dopamine transporters (DATs) and it
thereby accumulates and eventually kills these cells. Why
MPP+ spares the astrocytes in which it is supposedly
generated and how MPP+ leaves these cells have been
a vexing enigma for decades. We found here that MPP+
is generated extracellularly and that the release of
its membrane-permeable precursor 1-methyl-4-phenyl-
2,3-dihydropyridinium (MPDP+)/1-methy-4-phenyl-
1,2-dihydropyridine (1,2-MPDP) from astrocytes is
transporter independent. Differences in O2 and pH be-
tween the intra- and extracellular environment favor the
stabilization of the labile MPTP intermediate, MPDP+/
1,2-MPDP, within astrocytes and promote its nonenzy-
matic conversion in the extracellular space.
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DAT blocker, GBR12909, while in OCT3-IMAs, MPP+ up-
take was prevented by the OCT3 blocker, D22 (Supple-
mentary Fig. S1A–D).
We next assessed the response of wild-type and the
transporter-expressing cell lines to MPP+ treatment. All cells
were exposed to a fixed concentration (20 lM) of extracel-
lular MPP+ (Fig. 1E). The toxicant did not enter wild-type
IMAs, which was as expected given the absence of functional
carriers in the plasma membrane in these cells and the in-
ability of MPP+ to cross lipid bilayers. Strong intracellular
accumulation was, however, observed in DAT-IMAs. Ectopic
OCT-3 expression in OCT3-IMAs and OCT3/DAT-IMAs
enabled influx of MPP+ into cells. In OCT-3/DAT-IMAs,
MPP+ efflux from cells that had accumulated very high
FIG. 1. Formation and release of MPP1 by astrocytes. The mouse astrocyte cell line, IMA 2.1 (A), and primary mouse
glial cells (B) were incubated with MPTP (30 lM) for the indicated time intervals. MPTP and MPP+ were measured in the
supernatant by high performance liquid chromatography (HPLC) analysis. (C) A schematic overview of MPTP conversion
by astrocytes. In the first step, MPTP is oxidized by mitochondrial MAO-B. In the second step, the intermediate undergoes a
nonenzymatic autoxidation to form MPP+. Intracellular formation of MPP+ would imply either an accumulation within
mitochondria driven by their membrane potential (DJ) or a transporter-mediated passage across the membrane. The
primary export mechanism for MPTP metabolites we propose herein assumes the formation of a membrane-permeable
intermediate that diffuses across the plasma membrane and ultimately forms MPP+ in the extracellular space. (D) IMAs
were exposed to MPTP (20 lM) for the time intervals indicated, and intracellular and extracellular (supernatant) MPP+
levels were analyzed. (E) IMA wild-type cells (wt) or transgenic cells stably expressing the OCT3, the DAT, or a combination
of both were exposed to MPP+ (20lM) for the time periods indicated, and intracellular MPP+ was measured. (F) IMA clones
were exposed to MPP+ (20lM) for 2 h to allow for saturation of uptake. Intracellular MPP+ concentrations were calculated
from measured MPP+ amounts in cell homogenates and cell volumes that were in the range of 2.5 pl/cell. (G) IMA transgenic
cells expressing OCT3, DAT, or a combination of both were exposed to varying MPP+ concentrations for 24 h, viability was
then assessed by the resazurin reduction assay. All data are mean – SD (n = 3) *p < 0.05. DAT, dopamine transporter; IMA,
immortalized mouse astrocytes; MAO-B, monoamine oxidase B; MPP+, 1-methyl-4-phenyl-pyridinium; MPTP, 1-methyl-
4-phenyl-tetrahydropyridine; OCT3, organic cation transporter-3; SD, standard deviation. To see this illustration in color,
the reader is referred to the web version of this article at www.liebertpub.com/ars
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concentrations of MPP+ due to DAT activity was observed
(Fig. 1E). Steady-state levels were reached within 2 h. At this
time point, the absolute amount of accumulated MPP+ was
measured and the cellular volume of IMAs was determined
(2.5 pl/cell) so that average intracellular MPP+ concen-
trations could be calculated (Fig. 1F). The transporter-
expressing cells reached levels of around 180–680 lM, which
are highly similar to tissue concentrations found in mice
exposed to MPTP (19). Within 24 h, these concentrations
were sufficient to diminish the cellular capacity to reduce
resazurin or to produce ATP (Supplementary Fig. S2). By
contrast, IMAs neither accumulated MPP+ nor displayed
impaired viability in response to up to a 120lM concentra-
tion of extracellular MPP+. Indeed, the degree of MPP+-
induced reductions in viability across the four cell lines
correlated with their respective capacity to accumulate MPP+
(Fig. 1G). These data support the notion that astrocytes are
not resistant to MPP+ toxicity as reduced viability was ob-
served as soon as MPP+ accumulated within the transporter-
expressing cells. Our findings also confirm that MPP+ cannot
cross the membranes of IMAs unless they ectopically express
MPP+ transporters. This led us to posit that MPP+ crossed the
IMA membrane through an OCT-3-independent mechanism
during the course of MPTP metabolism.
MPDP + is a membrane-crossing intermediate
generated from MPTP by MAO-B
Since the pioneering work of Castagnoli et al., it has been
known that MAO-B converts MPTP to intermediates such as
MPDP+ and that further oxidation to MPP+ proceeds none-
nzymatically (4, 30, 39). Some of these initial publications
speculated that these intermediates might play a role in
transport processes, but further investigation of their bio-
logical formation and properties over the last 30 years has
been highly limited. We thus focused here on the transport of
MPDP+ as a potential missing link that might explain extra-
cellular MPP+ formation. Analysis of the products formed in
the conversion of MPTP by purified MAO-B enzyme con-
firmed that MPDP+ is a major intermediate in the generation
of MPP+ (Fig. 2A). Similar observations were made in the
analysis of wild-type IMA and OCT3-IMA cultures treated
with MPTP as MPDP+ was detected in the supernatant before
MPP+. We further found that MPDP+ export was not de-
pendent on OCT3 (Fig. 2B). To determine if MPDP+ for-
mation in this in vitro model also occurs in vivo, mice were
injected with MPTP and the striatum and cerebellum were
collected from injected mice at different time intervals. These
experiments revealed a rapid (30 min) rise of MPDP+ in both
brain areas that preceded the formation of MPP+. MPP+ re-
mained elevated in the striatum, but not in the cerebellum
(Fig. 2C). C-5 carbons of tetrahydropyridine structures such
as MPDP+ are acidic (i.e., they possess an a,b-unsaturated
iminium ion structure). However, their conjugate free base
form, 1,2-MPDP, was also observed (4, 30, 39) (Fig. 2D) and
this molecule is expected to be able to freely diffuse across
biological membranes. To more carefully examine the
formation of intermediates that are generated in the MAO-
dependent conversion of MPTP to MPP+, we conducted time-
resolved 1H-NMR analysis (Supplementary Fig. S3). These
data confirmed a significant time lag between the enzymatic
formation of MPDP+ and its subsequent autoxidation to
MPP+. Based on these findings, we hypothesized that the
acid–base pair, MPDP+/1.2-MPDP, serves as a membrane-
permeable intermediate in MPP+ production that is exported
from astrocytes and would thereby explain the presence of
extracellular of MPP+.
Free bidirectional flux of MPDP+/1.2-MPDP across
biological membranes
To test the hypothesis that MPDP+/1.2-MPDP possesses
transporter-independent membrane permeability, IMAs were
treated with 50 lM fresh MPDP+ or decomposed MPDP+
(stored in an open tube at room temperature before use). Both
the resazurin reduction assay and measurements of intracel-
lular ATP (Fig. 2E) indicated that only fresh MPDP+ led to
cell damage. For an appropriate interpretation of the data, it is
important to note that the extracellular volume in these ex-
perimental setups is substantially greater than the intracel-
lular volume. Treatment of the cells with MPTP hence results
in a constant and steep concentration gradient of freshly
generated MPDP+ that supports its efflux into the extracellular
space. In contrast, extracellular addition of MPDP+ generates
conditions in which the intracellular volume is rapidly satu-
rated (i.e., intracellular volume <<< extracellular volume).
To confirm a direct influence of intracellular MPP+ on
mitochondria, metabolic flux measurements were obtained as
a more sensitive readout. MPP+ specifically inhibits complex
I of the electron transport chain. As a result, nicotinamide
adenine dinucleotide (reduced) (NADH) cannot be oxidized
via complex I and accumulates in the cell. An increase in the
NADH (reduced)/NAD+ (oxidized) ratio results in an inhi-
bition of NAD+-dependent reactions of the TCA cycle, such
as pyruvate dehydrogenase activity. In the case of complex I
inhibition, glucose carbon contribution to the TCA cycle
strongly decreases, while pyruvate reduction to lactate in-
creases. By increasing the rate of glycolysis, the cell com-
pensates for the lack of ATP, similar to the Warburg effect.
To assess metabolic flux, we labeled cells with the tracer
[U-13C6] glucose, which can be used to monitor relative pyru-
vate oxidation that results from the NAD+-dependent pyruvate
dehydrogenase reaction decarboxylating pyruvate in the mito-
chondrion during the production of acetyl-CoA (Fig. 2F). The
activities of pyruvate dehydrogenase and of ATP-dependent
pyruvate carboxylase were both inhibited by MPDP+, but not
by MPTP or MPP+ (Fig. 2F, Supplementary Fig. S4).
To directly compare MPP+ and MPDP+ uptake, intracel-
lular MPP+ levels in IMAs exposed to either MPP+ or MPDP+
were investigated. To exclude any potential involvement of
cellular transporter systems, all experiments were conducted
in parallel with artificial lipid vesicles (Fig. 3A). As a third
model system, purified human erythrocytes were used as they
possess no MPP+ transporter activity, but do allow the
conversion of MPDP+ to MPP+ due to the presence of iron-
containing hemoglobin. In all three model systems, extra-
cellular concentrations of MPP+ as high as 200lM did not
result in significant accumulation of intracellular MPP+,
while the addition of MPDP+ immediately led to the forma-
tion of intracellular/intravesicular MPP+. Uptake of MPDP+
and MPP+ into erythrocytes was then tested in vivo by
intravenous injection of these compounds into mice and
collection of blood after 3 min. Similar to the ex vivo treat-
ment of erythrocytes, the addition of MPDP+ resulted in the
1004 SCHILDKNECHT ET AL.
intracellular accumulation of MPP+, providing further evi-
dence of transporter-independent membrane passage of
MPDP+ (Supplementary Fig. S5).
To further test the kinetics of cell loading and unloading of
MPDP+, IMAs were exposed to MPDP+ (50lM) for a 30-min
loading phase. Analysis of the cellular compartment showed
a rapid increase of MPDP+, followed by a rise in MPP+
concentrations. MPP+ was apparently generated within these
cells as extracellular MPP+ cannot cross the cell membrane
(Fig. 3B, Left). After the loading phase, cells were washed,
new medium was added, and metabolite levels were detected
over time in both the intracellular (Fig. 3B, Middle) and ex-
tracellular compartments (Fig. 3B, Right). Accumulated
MPDP+ vanished rapidly from the cells into the extracellular
media, whereas intracellular MPP+ was not able to exit the
cells (Fig. 3B, Middle and Right). Considering these data
together, we concluded that extracellular MPP+ originated
from the autoxidation of extracellular MPDP+. In addition,
these findings indicate that the MPDP+ concentration gradient
is the predominant driving force underlying its transport across
membranes, which explains the apparent export of MPP+. These
observations indicate that MPDP+/1.2-MPDP is membrane
FIG. 2. MPDP1 generation precedes the formation of MPP+ in vitro and in vivo. (A) Purified MAO-B enzyme (1 U/
ml) was incubated with 30 lM MPTP for the time intervals indicated. In addition to MPP+, an intermediate was detected
that was identified as MPDP+. (B) Wild-type (wt) IMAs or OCT3-expressing IMAs were treated with MPTP (30 lM) for
various incubation periods, and MPP+ and MPDP+ levels in the extracellular medium were assessed. (C) Mice received an
intraperitoneal injection of MPTP (30 mg/kg) at t = 0 min. After the time intervals indicated, samples from the striatum and
the cerebellum were collected and analyzed by HPLC. (D) Structures of MPTP and its derivatives are shown. MPDP+
originates from the MAO-B-catalyzed two-electron oxidation of MPTP. Under physiological conditions, MPDP+ can also
exist in its uncharged and membrane-permeable base form, 1,2-MPDP. This intermediate is converted by nonenzymatic
autoxidation into MPP+. (E) IMAs were incubated with 50lM of MPTP, MPDP+, or decomposed MPDP+ for 18 h. Cell
viability was detected by the resazurin reduction assay and by analysis of intracellular ATP. (F) For an analysis of
intracellular fluxes of central carbon metabolism, IMAs were incubated with [U-13C6] glucose and treated with MPTP or
MPDP+ (50 lM) for 18 h. All data are mean –SD (n= 3) *p < 0.05. 1,2-MPDP, 1-methy-4-phenyl-1,2-dihydropyridine;
MPDP+, 1-methyl-4-phenyl-2,3-dihydropyridinium.
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permeable and suggest that MPP+ will remain in a given
biological compartment, unless transporters are present.
The role of extracellular MPDP+ autoxidation
in dopamine neuron toxicity
Our data heretofore have suggested that upon MPTP intoxi-
cation, MPDP+/1.2-MPDP would have the potential to freely
diffuse across the membranes of several cells and eventually
convert to MPP+ in any cell type adjacent to MAO-containing
glial cells. However, MPP+ accumulation is largely limited to
catecholaminergic neurons that take up the molecule via their
catecholamine transporter (e.g., DAT). To compare the re-
spective contribution of DAT-mediated MPP+ accumulation
and passive MPDP+/1.2-MPDP-dependent influx (Fig. 4A),
human dopaminergic neuronal cells, lund human mesence-
phalic neuron (LUHMES), which can accumulate extracellular
MPP+ viaDAT (46, 47, 48), were treated with MPP+ or MPDP+
(20lM) in the presence or absence of the DAT blocker,
GBR12909 (GBR). This compound blocks the uptake of MPP+
via DAT inhibition, but not MPDP+/1.2-MPDP as it is not a
DAT substrate. Metabolic flux was measured with labeled
[U-13C6] glucose, which provides a readout of the inhibition of
oxidative phosphorylation. Both MPP+ and fresh MPDP+ led to
mitochondrial inhibition, and GBR blocked toxicity in both
cases (Fig. 4B). These observations were confirmed by cellular
staining with an anti-b-III-tubulin antibody, which demon-
strated that pronounced neurite degeneration was triggered by
both MPP+ and fresh MPDP+, and these effects were completely
prevented by GBR (Fig. 4C). Taken together, these data suggest
that at the moderate MPDP+/1.2-MPDP concentrations (low
micromolar range) that exist in vivo, intracellular autoxidation
of MPDP+ would not be sufficient to generate damaging intra-
cellular MPP+ concentrations.
FIG. 3. The intermediate MPDP1 crosses biological membranes. (A) Uptake velocities of MPP+ and MPDP+ were
investigated by detecting intracellular MPP+ in IMAs incubated with 200 lM of the compound for various time intervals. To
exclude the involvement of cellular transporters or mitochondrial transmembrane potential, the same experimental setup
was conducted with artificial vesicles comprising 50 mol% DOPC and 50 mol% DOPE. Human erythrocytes were used as an
alternative cellular model with high endogenous iron content (hemoglobin), which facilitates the intracellular conversion of
MPDP+. (B) Bidirectional transport of MPDP+ across biological membranes was studied in IMAs loaded with 50lM
MPDP+ over the course of 30 min (left). Cells were then washed thrice, new medium was added, and the release of
intracellular MPDP+ and MPP+ (middle) into the medium (right) was detected. All data are mean – SD (n= 3) *p < 0.05.
DOPC, 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine.
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To explore whether toxic MPP+ can be formed within
neurons from freely diffusing and autoxidizing MPDP+,
LUHMES cells were exposed to high (200 lM) or low
(20 lM) MPDP+ concentrations in the presence or absence
of the DAT blocker, GBR. High extracellular MPDP+ levels
led to a DAT-independent accumulation of intracellular
MPP+ doses sufficient to inhibit mitochondria, whereas low
concentrations did not (Fig. 4D). Thus, toxicity evoked by
free diffusion of freshly generated MPDP+ in cells adjacent
to astrocytes may play only a marginal role. To test this
assumption, a coculture model containing IMAs (astro-
cytes) and LUHMES (neurons) was exposed to MPTP. This
led to neurotoxicity via glial-dependent generation of
MPP+. The addition of GBR completely inhibited neuro-
toxicity in this coculture system. These data confirm that
the passive diffusion of freshly generated MPDP+/1.2-
MPDP itself from glia immediately adjacent to LUHMES
cells was not able to evoke significant toxicity (Supple-
mentary Fig. S6).
Identification of physiological factors that promote
the autoxidation of MPDP+ in the extracellular space
The findings described thus far indicate that MPP+ needs to
be formed extracellularly to become a substrate for DAT and
thus induce neurotoxicity. We next explored how a prefer-
ential extracellular generation of MPP+ might proceed in
structures such as the brain with a high ratio between the
intra- and the extracellular volume. As oxygen levels are
likely to play a role in MPDP+ autoxidation, we studied this
environmental factor. High-resolution measurements of ox-
ygen concentrations in cells have provided evidence for steep
oxygen concentration gradients between the cytosol and
mitochondria (27, 36). This may result in average intracel-
lular oxygen concentrations that are significantly lower than
the interstitial levels in tissue or cell culture media (17, 51).
We found that the speed of MPP+ formation strongly de-
pended on oxygen levels and that MPDP+ is highly stable
under low oxygen conditions such as those that are typically
found near the respiring mitochondria (27, 36, 51) of astro-
cytes (Fig. 5A, B). Lower intracellular oxygen levels would
hence stabilize intracellular MPDP+, while at the higher ex-
tracellular oxygen tension, the nonenzymatic conversion into
MPP+ would be favored.
We posited that another important factor in determining
the rate of MPDP+ autoxidation might be the local pH. The
cytosolic pH of most cells in the body is typically lower than
in extracellular fluids and the blood. Local acidification is
largely driven by respiratory chain proton pump activity,
particularly around mitochondria. We observed an acceler-
ated autoxidation of MPDP+/1.2-MPDP under more alkaline
conditions (Fig. 5C, D), while more acidic conditions (e.g.,
close to mitochondria) stabilized MPDP+. The combination
of a more acidic pH and lower oxygen tensions (e.g., the
conditions typically encountered inside cells) strongly pre-
vented MPDP+ autoxidation (Fig. 5E, F).
FIG. 4. Transporter-independent uptake of MPDP1 into dopaminergic neurons. (A) Neuronal LUHMES cells en-
dogenously expressing the DAT allow either a transporter-independent uptake of the MPDP+/1,2-MPDP intermediate,
followed by intracellular autoxidation into MPP+, or a DAT-dependent uptake of MPP+ originating from the extracellular
autoxidation of MPDP+/1.2-MPDP. (B) As a sensitive readout for mitochondrial activity, glucose oxidation was monitored
in LUHMES cells treated with MPP+ or MPDP+ (20 lM) by the addition of [U-13C6] glucose in the presence or absence of
the DAT blocker, GBR (1 lM), for 18 h. (C) The morphology of LUHMES cells treated with MPP+ or MPDP+ (20 lM) in
the presence or absence of GBR (1 lM) for 24 h was visualized by staining with an anti-b-III-tubulin antibody. (D) To
determine the respective contribution of DAT-dependent and independent uptake, LUHMES cells were incubated in low
(20 lM) or high (200 lM) MPDP+ concentrations. Intracellular levels of ATP and MPP+ were detected after 24 h. All data
are mean –SD (n= 3) *p < 0.05. LUHMES, lund human mesencephalic neuron. To see this illustration in color, the reader is
referred to the web version of this article at www.liebertpub.com/ars
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FIG. 5. Modulation of the nonenzymatic conversion of MPDP1 into MPP1. (A) MPDP+ (100 lM) was kept under
atmospheric conditions in DMEM medium at 37C or under oxygen-free conditions (B) for the time intervals indicated.
MPP+, MPDP+, and MPTP were detected by HPLC. (C, D) MPDP+ (100lM) was maintained in potassium phosphate buffer
with varying pH, as indicated in each time interval. Autoxidation of MPDP+ into MPP+ was monitored photo-
spectrometrically. (E, F) MPDP+ (100lM) was kept under atmospheric (E) or oxygen-free conditions (F) in potassium
phosphate buffer of different pH at 37C for the indicated incubation intervals. (G, H) To identify the influence of
metabolites of the dopamine pathway and physiologically relevant iron-containing molecules, MPDP+ (100 lM) was treated
with the indicated compounds (100lM each) under aerobic conditions with a pH of 7.4. All data are mean – SD (n= 8)
*p < 0.05.
1008 SCHILDKNECHT ET AL.
Based on these findings, we hypothesized that in addition
to DAT activity, the conditions in brain regions enriched in
dopaminergic neurons might promote greater autoxidation
than in other areas. The nigrostriatal system of the basal
ganglia has a particularly high iron content and also contains
various autoxidation products of dopamine (12, 35). All of
these compounds promote the formation of radicals, which
are required for autoxidation of MPDP+. While free radicals
have very short half-lives inside cells due to several efficient
free radical buffering mechanisms (e.g., glutathione system,
iron buffering), they can persist for longer times extracellu-
larly. Taking this into consideration, several candidates were
tested for their influence on MPDP+ autoxidation. A striking
acceleration of MPP+ genesis from MPDP+ was observed in
response to the treatment with autoxidized dopamine, mela-
nin, iron-containing ferritin, or with free ferrous iron (Fig.
5G, H). Addition of the iron chelator, deferoxamine, pre-
vented the iron-mediated acceleration of MPDP+ autoxida-
tion (Supplementary Fig. S7). This is in accordance with
reports indicating a protective role of iron chelators in MPTP
PD models (11, 29), although these reports did not demon-
strate whether the conversion of MPTP was affected by
treatment with iron chelators or other oxidative stress-related
events. Enhanced autoxidation in the extracellular milieu
would not only explain preferential MPP+ generation outside
cells but also ensures there is a constant, steep concentra-
tion gradient between cytosolic MPDP+ and extracellular
MPDP+, which is the main driving force for its transporter-
independent efflux (Fig. 6).
Discussion
Among the known human neurotoxicants, MPTP is ex-
ceptional, in that it triggers relatively selective death of ni-
grostriatal DA neurons upon systemic administration (3, 25,
31). A necessary prerequisite for the selective DAT-dependent
uptake of the active toxin MPP+ is the presence of MPP+ in the
extracellular space, as was elegantly confirmed by several
microdialysis studies (9, 21, 33). The mechanism by which
MPP+, a membrane-impermeable molecule generated intra-
cellularly by the enzymatic conversion of MPTP, reaches the
extracellular space has been elusive. The present work aimed
at addressing this question and was inspired by the observa-
tion of efficient extracellular MPP+ generation in MPTP-
converting astrocytes in the absence of significant intracel-
lular MPP+ accumulation and toxicity.
We first determined that astrocytes (IMAs) were not im-
mune to MPP+ as these cells died when cytosolic accumu-
lation of extracellular MPP+ was enabled by the ectopic
expression of the MPP+ transporters, DAT and/or OCT3.
Although it can be concluded from these results that astro-
cytes are not per se resistant to MPP+, they do have the ca-
pacity to accelerate glycolytic turnover and hence are able to
at least partially compensate for inhibited mitochondrial ATP
synthesis caused by MPP+. This conclusion is corroborated
by several experiments in the literature showing that any cell
tested thus far, for example, HEK293, hepatocytes, COS, or
HeLa cells, is killed by MPP+ if the toxicant is allowed to
enter the cytosol.
Moreover, the findings of the present study provide a ra-
tionale for why cells that metabolize MPTP with endogenous
MAO, such as astrocytes, platelets, and hepatocytes, are not
necessarily killed by the final reaction product, MPP+. We
found that the intermediate MPDP+ (or its neutral base 1.2-
MPDP) exits cells along a concentration gradient via mem-
brane diffusion. MPP+ is mainly formed extracellularly and,
in most cases, it would be diluted and carried away by body
fluids or taken up by passive transporters in neighboring cells.
In most cells, MPP+ accumulation would therefore be tran-
sient and minimal as MPDP+/1.2-MPDP would exit the cell
as soon as the extracellular concentration drops. Only cells
that accumulate MPP+ through an active intracellular trans-
port mechanism, for example, DA neurons in the central
nervous system, would therefore be able to retain the toxicant
for a sufficient period of time and at high enough concen-
trations to cause damage (Fig. 6). While accumulation of
MPP+ in cells is a necessary condition for the toxicity of this
molecule, the degree of susceptibility of particular cell types
to intracellular MPP+ may vary due to the presence or ab-
sence of resistance mechanisms, for example, by sequestra-
tion as in adrenomedullary cells (43) or other more poorly
understood cellular factors (7, 46). Alternatively, certain cells
may possess factors that promote MPP+ formation and tox-
icity; for instance, cytochrome P-450 2D6 was recently
suggested to directly contribute to the conversion of MPTP in
neuronal cells (1). By contrast, in LUHMES cells, MPTP
treatment resulted in neither the formation of MPP+ nor
cellular degeneration (not shown).
The concentration of MPP+ required to cause toxicity in
different cell types may therefore vary. Studies of isolated
mitochondria and submitochondrial particles have shown
that MPP+ concentrations of about 5–20 mM need to be
reached in the mitochondrial matrix for inhibition of complex
I (40, 41), which would in turn require cytosolic levels in the
high micromolar range (>100lM). This is corroborated by
our measurements showing mitochondrial effects and toxic-
ity within a period of 24–48 h in IMAs expressing OCT3
or DAT if intracellular MPP+ concentrations were larger
than 100 lM (Fig. 1F). By contrast, our measurements of
wild-type IMAs showed that concentrations were*10 lM
(& 1 nmol/mg protein), which is in close accordance with the
FIG. 6. MPDP1/1,2-MPDP is the main exported form
of MPTP metabolites. MAO-B-dependent conversion of
MPTP in astrocytes yields MPDP+ that partially exists in its
conjugate base form, 1,2-MPDP, and is able to freely diffuse
across biological membranes. Conditions with an alkaline
pH, elevated O2 tension, iron-containing proteins, or neu-
romelanin promote accelerated autoxidation of MPDP+ in
the extracellular space. Due to its charge, stable MPP+ re-
quires transporters such as the DAT or the OCT for cellular
uptake.
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data of Di Monte et al. obtained from primary mouse astro-
cyte cultures (1 nmol/mg after a 48-h exposure to 250lM
MPTP) (15, 16, 55).
In this study, we have demonstrated that MPDP+ is the
pivotal MPTP metabolite responsible for the extracellular
genesis of MPP+, which minimizes its toxicity to most cell
types. MPDP+ was described and synthesized by Cas-
tagnoli et al. in the 1980s (4, 5). Their pioneering dis-
covery of this metabolite and the seminal work of Di
Monte et al. (13–16, 55) were quickly incorporated into all
major toxicology textbooks, but experimental study of this
compound has been virtually nonexistent for the past 25
years, despite its wide use in PD research during this time.
In this study, we have advanced this early work by pro-
viding direct evidence by NMR and MS of MPDP+ for-
mation during MPTP to MPP+ conversion by MAO-B. It
was originally postulated that the disproportionation of
two molecules of MPDP+ into MPP+ and MPTP would be
the dominating mechanism of MPP+ formation; however,
our previous studies on the autoxidation of resynthesized
MPDP+ suggest that direct oxidation of MPDP+ into MPP+
dominates (4, 5). Although the mechanism of MPDP+
autoxidation has not yet been fully elucidated, kinetic and
thermodynamic principles observed in structurally related
compounds allow us to postulate that the reaction sequence
is as follows: in the initial step, a stabilized allyl radical is
formed by the abstraction of a proton at C5 as a result of
the interaction of MPDP+ with molecular oxygen (O2),
transition metals, or free radical species (e.g., dopamine
autoxidation products) (Supplementary Fig. S8); in a sec-
ond reaction, the allyl radical interacts with a second free
radical species or O2; when there is an interaction with O2,
C-5 would carry a peroxide group, which would render the
carbon 6 acidic and hence trigger the release of a proton
from C-6 (peroxometabolite); energetically, the elimina-
tion of the C-5 hydroperoxide substituent from the base
form would strongly favor aromatization to the stable
toxin MPP+ (Supplementary Fig. S8); and the final step of
proton abstraction from the peroxometabolite is favored
under alkaline conditions. This sequence of events is
strongly supported by our experimental observations in-
dicating accelerated MPDP+ autoxidation in the presence
of high oxygen levels and transition metals and a relative
stabilization under slightly acidic conditions (Fig. 5). Im-
portantly, autoxidation can efficiently proceed under con-
ditions of relatively low MPDP+ concentrations in contrast
to disproportionation reactions.
We have identified several factors that increase MPP+
formation in the extracellular space, most notably higher
oxygen tension and pH. Indeed, the low oxygen levels within
cells compared with the extracellular space may be reduced
even further in astrocytes by MAO-B metabolism of MPTP,
which is an oxygen-consuming reaction (6). Thus, low oxy-
gen tensions and lowered pH around respiring astrocytes
would prevent MPP+ formation within cells, while this pro-
cess would proceed faster in the extracellular space. More-
over, our data show that MPTP conversion proceeds more
than 10 times faster in the presence of biological oxidation
enhancers, such as melanin, oxidized dopamine, or ferrous
iron. Some of these factors have particularly high levels not
only in the nigrostriatal system, in which DA neurodegen-
eration prevails, but also in hemoglobin-carrying erythro-
cytes (Fig. 3A and Supplementary Fig. S5) (50, 53, 56).
These factors are neutralized and scavenged to a large extent
inside cells due to powerful redox buffers, lysosomal re-
moval, or iron binding by ferritin, while they may exert their
full activity in the extracellular space. Apart from oxygen
tension or pH, other factors might indeed influence the au-
toxidation of MPDP+. Our observation of accelerated MPDP+
autoxidation induced by ferrous iron and its inhibition by the
iron chelator, deferoxamine (Supplementary Fig. S7), pro-
vides insight into the molecular mechanisms that might un-
derlie previous observations of protection against MPTP
toxicity in vivo by iron chelator administration to model an-
imals (11, 29). However, we tested ascorbic acid in a cell-free
model of MPDP+ autoxidation as well as in IMAs that were
exposed to MPTP. In both cases, the autoxidation of MPDP+
and the formation of MPP+ were not affected (Supplementary
Fig. S7). These findings indicate that a more detailed analysis
of the molecular mechanisms involved is required.
A recent study reported that there is selective expression of
OCT3 in glial cells located in close spatial vicinity to ni-
grostriatal neurons that were primarily affected in MPTP-
challenged brains. This suggested that preferential MPP+
release from astrocytes via OCT3 would be a major con-
tributing factor in the selective loss of DA neurons in the
substantia nigra (9). However, we observed that MPDP+
generation in the brains of MPTP-treated mice preceded the
formation of MPP+ not only in the substantia nigra but also in
the cerebellum, which is a prerequisite for the transporter-
independent efflux of MPDP+ into the extracellular space
(Fig. 2). A recent publication was in full accordance with our
findings in demonstrating almost uniform MPP+ generation
in MPTP-exposed brains only minutes after MPTP admin-
istration. This was followed by rapid clearance from the
brain, except in the basal ganglia, ventral mesencephalon,
and olfactory bulb (28). Given the findings that MPP+ is
generated globally in the extracellular space and taken up by
specific cell types due to selective transporter expression, the
tissue distribution of MPP+ may be determined by complex
dynamics that owe to the differential expression of MPP+
transporters across cell types and brain regions. For instance,
MPP+ would be partially sequestered into cells expressing
OCTs (Fig. 6), as indicated by our experiments with OCT-3-
expressing IMAs (Fig. 1). Indeed, such a mechanism has been
reported in vivo for the MPP+-related compound, paraquat,
which resulted in the protection of DA neurons in brains of
paraquat-treated mice by lowering extracellular concentra-
tions of the toxin (42).
The basic principles identified in the present work are not
only limited to the experimental toxin, MPTP, but could also
apply to endogenously formed small molecules, such as
quinolinic acid (34), isoquinolines, beta-carbolines (8), or
dopamine autoxidation products (2), all of which are sus-
pected to play key roles in neurological and psychiatric dis-
orders.
Materials and Methods
Materials
MPP+ (1-methyl-4-phenyl-pyridinium-iodide), purified
MAO-B, GBR12909 (DAT blocker), dopamine, ferritin, and
tyrosine–melanin were purchased from Sigma-Aldrich (St.
Louis, MO).
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Synthesis of MPTP-HCI and MPDP+ bromide
All reagents are commercially available and were used
without further purification. Solvents were dried over
molecular sieves and used directly without further puri-
fication. All reactions were conducted under exclusion of
air and moisture. 1H- and 13C-NMR spectra were re-
corded on an Avance III 400 MHz spectrometer from
Bruker at room temperature. The time course of enzy-
matic MPTP conversion was followed on a Bruker AV III
600 MHz spectrometer equipped with a TCI cryoprobe.
Spectra were processed with the software MestReNova
6.1.1 from MestRelab Research, and the 1H and 13C
chemical shifts are reported relative to the residual sol-
vent peak. High-resolution mass spectrometry (HRMS)
was performed with micrOTOF-Q II ESI-Qq-TOF from
Bruker Daltonics (Fig. 7).
Step a): 1-Methyl-4-phenyl-4-piperidinol 3 (18). A solu-
tion of 24.6 ml phenyllithium 2 (1.8 M in dibutyl ether) was
added to a solution of 1-methyl-4-piperidone 1 (5 g, 44.19
mmol) in 20 ml of dry tetrahydrofuran at -78C. The reaction
was allowed to warm up to room temperature and was stirred
overnight. The solvents were removed in vacuo to give crude
3 as a yellowish solid.
Step b): MPTP-HCI 4 (18). Refluxing of crude 3 in 50 ml
10% aq HCl for 5 h furnished compound 4. The solvent was
removed in vacuo and crude 4 was recrystallized from eth-
anol to give white crystalline 4 in a quantitative yield.
1H-NMR (400 MHz, CD3OD) d 7.53–7.47 (m, 2H), 7.44–
7.31 (m, 3H), 6.15 (ddd, J = 5.1, 3.4, 1.7 Hz, 1H), 4.08 (d,
J = 15.3 Hz, 1H), 3.92–3.79 (m, 1H), 3.79–3.70 (m, 1H),
3.45–3.35 (m, 1H), 3.03 (s, 3H), 3.00–2.92 (m, 1H), 2.87 (d,
J = 21.4 Hz, 1H).
1H-NMR (600 MHz, D2O) d 7.55–7.52 (m, 2H), 7.46 (dd,
J = 10.2, 4.8 Hz, 2H), 7.43–7.39 (m, 1H), 6.15–6.13 (m, 1H),
4.05 (d, J = 16.4 Hz, 1H), 3.82–3.78 (m, 1H), 3.74–3.69 (m,
1H), 3.43–3.34 (m, 1H), 3.00 (s, 3H), 2.96–2.90 (m, 1H), 2.86
(d, J = 19.0 Hz, 1H).
13C-NMR (101 MHz, CD3OD) d 139.9, 136.8, 129.7,
129.4, 126.2, 116.6, 53.5, 52.0, 42.9, 25.8.
13C-NMR (150 MHz, D2O) d 138.3, 134.6, 128.7, 128.4,
125.0, 115.5, 52.0, 50.6, 41.7, 23.8.
HRMS (ESI, positive ion mode): [M+H]+; calculated:
C12H15N: 174.1277 m/z; measured: 174.1288 m/z.
Step c): 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine N-
Oxide 5 (20).
(i) The solution of 4 (2.31 g, 11.01 mmol) in 60 ml
ethanol was cooled to 0C and 9.5 ml of a sodium
ethoxide solution (1.17 M in ethanol, 11.12 mmol)
was added. The mixture was filtered over celite and
the filter cake was washed with 30 ml of ethanol.
(ii) Next, 2.6 ml of 30% aq H2O2 was added and the
mixture was stirred at 50C. After 2 h, an additional
portion of 2ml 30% aq H2O2 was added and it was
stirred overnight. Afterward, the excess of H2O2 was
quenched with 10% Pd/C. The resulting mixture was
filtered over celite and the filter cake was washed
with 30 ml of ethanol. The solvent was removed in
vacuo to give 5 2 H2O as yellow oil in a quantitative
yield.
1H-NMR (400 MHz, CDCl3) d 7.42–7.26 (m, 5H), 5.96 (s,
1H), 4.32–4.10 (m, 2H), 3.76–3.65 (m, 2H), 3.37 (s, 3H),
3.06–2.95 (m, 1H), 2.76–2.62 (m, 1H).
Step d): MPDP+ bromide 6 (20). The suspension of 5 2
H2O (2.51 g, 11.01 mmol) in 90 ml dichloromethane
(DCM) was cooled to 0C and trifluoroacetic anhydride
(4.49 g; 21.38 mmol) was added dropwise within 20 min. It
was stirred at 0C for 2 h, followed by the addition of 48%
aq HBr (2.06 g, 12.23 mmol). The mixture was evaporated
to dryness under reduced pressure at room temperature.
The resulting crude product was recrystallized from ace-
tone to yield 53% 6 (1.48 g, 5.87 mmol) as a yellow hy-
groscopic solid.
1H-NMR (400 MHz, CDCl3) d 9.23 (d, J = 4.1 Hz, 1H),
7.69–7.60 (m, 2H), 7.52–7.40 (m, 3H), 6.89 (d, J= 4.6 Hz,
1H), 4.14 (t, J = 9.4 Hz, 2H), 3.93 (s, 3H), 3.32 (t, J = 9.4 Hz,
2H).
1H-NMR (600 MHz, D2O) d 8.38 (d, J = 4.8 Hz, 1H), 7.82
(d, J= 7.9 Hz, 2H), 7.63–7.54 (m, 3H), 6.90 (d, J= 5.0 Hz,
1H), 4.04 (t, J = 10.1 Hz, 2H), 3.69 (s, 3H), 3.28 (t,
J= 10.1 Hz, 2H).
13C-NMR (101 MHz, CDCl3) d 164.1, 158.0, 134.5, 133.0,
129.5, 127.3, 113.9, 49.0, 47.7, 25.6.
13C-NMR (150 MHz, D2O) d 163.5, 158.8, 134.6, 132.5,
129.0, 126.7, 112.9, 47.6, 46.0, 24.5.
HRMS (ESI, positive ion mode): [M]; calculated
C12H14N
1: 172.1121 m/z; measured: 172.1124 m/z.
Analysis of 1-methyl-4-phenylpyridinium iodide (MPP+
I-) (Sigma-Aldrich)
1H-NMR (400 MHz, DMSO) d 9.02 (d, J = 6.9 Hz, 2H),
8.51 (d, J = 7.0 Hz, 2H), 8.11–8.04 (m, 2H), 7.70–7.61 (m,
3H), 4.34 (s, 3H).
a b c d
FIG. 7. Synthesis of
MPTP-HCI (4) and MPDP+
bromide (6). (a) THF, -
78C/ rt, overnight; (18) (b)
aq HCl, reflux, 5 h, quantita-
tive; (18) (c) (i) NaEtO, EtOH,
0C (ii) aq H2O2, EtOH, 50C,
quantitative; (20) (d) DCM,
TFAA, aq HBr, 0C, 53%.
(20). TFAA, trifluoroacetic
anhydride; THF, tetrahydro-
furan.
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1H-NMR (600 MHz, D2O) d 8.74 (d, J = 6.7 Hz, 2H), 8.28
(d, J = 6.7 Hz, 2H), 7.97–7.92 (m, 2H), 7.70–7.62 (m, 3H),
4.36 (s, 3H).
13C-NMR (101 MHz, DMSO) d 154.3, 145.6, 133.5,
132.0, 129.7, 128.0, 124.1, 47.1.
13C-NMR (150 MHz, D2O) d 156.3, 144.8, 133.8, 131.9,
129.5, 127.7, 124.6, 46.9.
HRMS (ESI, positive ion mode): [M]; calculated
C12H12N
+: 170.0964 m/z; measured: 170.0968 m/z.
LUHMES cell culture
Methods for the generation, handling, and properties of
LUHMES cells have been described in detail previously (47,
48). The cells were grown in standard conditions (serum-
free) at a density of 300,000 cells per well in 24-well plates.
The cells were derived from human fetal mesencephalon and
were conditionally immortalized by expression of v-myc
under a tet-off promoter. Upon addition of tetracycline,
LUHMES cells differentiate within 5 days to fully post-
mitotic human dopaminergic neurons with neurites of up to
1000 lm length (48). At this stage, the cells express highly
active DATs and are susceptible to low micromolar levels of
MPP+ (47, 48). For uptake experiments, cells were differ-
entiated for 6 days and plated at a density of 300,000 cells/
well in 24-well plates.
IMA 2.1 astrocytes
Generation and properties of the IMA cell line have re-
cently been described in detail (45). These IMAs were cul-
tured at 37C (5% CO2) in DMEM (normal glucose)
(GIBCO) with 10% FCS (fetal calf serum from PAA) and 1%
penicillin/streptomycin (10,000 U/ml stock). The cells were
passaged by trypsinization for 2 min with 0.5% trypsin/
DMEM every 2–3 days and reseeded at a ratio of 1:5 or 1:10.
Experiments were performed 2 days after cells reached
confluency in DMEM containing 10% FCS.
Overexpression of OCT3 and DAT
Gene contracts for human solute carrier family 6, member 3
(DAT), and sls22a solute carrier family 22, member 3 (OCT3),
were purchased from SourceBioscience (Berlin, Germany).
Both were obtained as inserts in the polymerase chain reaction
vector (Invitrogen, Life Technologies Corporation) as clone
number IRCBp5005O019Q (40147025- IMAGE ID) and
clone number IRCKp5014K038Q (8860680- IMAGE ID),
respectively. The DAT gene was cloned into the phsCtR2AU-
W expression construct. This HIV-based vector was used as
a plasmid to transfect the IMA cell line using Lipofectamine
(Invitrogen, Life Technologies, Darmstadt, Germany). In
this construct, the DAT gene was fused to the 3¢ end of the
tR2AU cassette (turbo red fluorescent protein from En-
tacmaea quadricolor, the 2A sequence of porcine tescho-
virus, and human ubiquitin sequences). Translation of this
gene produces free tRFP protein by ribosomal skipping at
the 2A site and free DAT protein by the action of cellular
hydrolases, which cut at the 3¢ end of the ubiquitin peptide.
Cells that were successfully transfected and expressed
the DAT gene could therefore be identified by their ex-
pression of red fluorescence. Cells were assayed 3 days after
transfection.
The gene for OCT3 was cloned into the pBIGFP vector.
This construct contains a bidirectional inducible promoter
allowing the expression of any gene cloned therein and the
simultaneous expression of the linked marker gene eGFP
(enhanced green fluorescent protein). Induction levels can be
monitored by examination of eGFP intensities. Cells were
transfected using Lipofectamine (Invitrogen, Life Technol-
ogies Corporation, Darmstadt, Germany) and subsequently
selected with 200lg/ml G418 for 10 days.
Immunostaining
Cells were grown in 24-well, plastic cell culture plates
(Nunclon). Following treatment, cells were fixed with 4%
paraformaldehyde (PFA) for 20 min at 37C and washed with
phosphate-buffered saline (PBS). After blocking with 1% bo-
vine serum albumin (Calbiochem, San Diego, CA) for 1 h, the
primary antibody (anti-b-III-tubulin, Convance, mouse 1:1000)
was added in PBS-Tween (0.1%) and the cells were incubated
at 4C overnight. Secondary antibody (anti-rat IgG-Alexa 488,
Invitrogen, Darmstadt, Germany) was added for 45 min at RT.
For visualization, an Olympus IX 81 microscope (Hamburg,
Germany) equipped with an F-view CCD camera was used.
Images were processed by Cell P software (Olympus).
Cell viability
Resazurin (Sigma-Aldrich) was added to the cell culture
medium at a final concentration of 5 lg/ml and incubated at
37C for at least 30 min. The fluorescence intensity was
measured at 530 nmex and 590 nmem with a Tecan Infinite
M200 reader. Cell viability (in %) was calculated by nor-
malizing the fluorescence values to the values obtained from
untreated controls.
ATP assay
Cells grown in 24-well plates were lysed in PBS buffer
containing 0.5% phosphatase inhibitor cocktail 2 (Sigma-
Aldrich) and boiled at 95C for 10 min. Following centrifu-
gation at 10,000 g for 5 min to remove cell debris, protein
content in the supernatant was measured and samples were
adjusted to have equal concentrations. Samples were then
diluted 1:10 in PBS/0.5% phosphatase inhibitor buffer. For
the detection of ATP levels, a commercially available ATP
assay reaction mixture (Sigma-Aldrich) containing luciferin
and luciferase was used (50ll of adjusted sample plus 100ll
of assay mix was added to a black 96-well plate). Standards
were prepared by serial dilutions of ATP disodium salt hy-
drate (Sigma-Aldrich) to obtain concentrations ranging from
1000 to 7.8 nM.
Vesicle uptake assay
For vesicle preparation, stock solutions of 100 mg/ml DOPC
(1,2-dioleoyl-sn-glycero-3-phosphocholine) and 100 mg/ml
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine)
(Avanti) in CHCl3 were prepared. For the production of a 2 ml
vesicle suspension, 102 ll of DOPC and 98 ll of DOPE stock
solutions were mixed in a glass tube and evaporated for 30 min
under vacuum while rotating to remove CHCl3. The lipid film
was then resuspended in 1 ml of 20% Triton X-100 in PBS,
and air was removed by N2 degassing. The mixture under N2
atmosphere was then briefly sonicated in a water bath and
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allowed to rest at room temperature until a clear solution was
observed, indicating complete solubilization of the lipids. To
remove the detergent, 600 mg Bio-Beads SM-2 (Bio-Rad)
pre-equilibrated in PBS were added to the clear lipid/deter-
gent mixture diluted 1:1 in PBS and incubated at 4C on a
rotator for 16 h. For removal of the beads, the vesicle sus-
pension was collected with capillary tips and transferred to a
separate tube. For uptake assays, the vesicle suspension
(10 mg lipids/ml) in PBS was incubated with MPP+ or MPDP+
for 2 h at 37C. To remove free MPP+/MPDP+, vesicles were
separated by loading 100 ll of the sample onto an NAP-5
Sephadex G-25 column and a stepwise addition of 250ll
volumes of PBS for elution. As control, vesicle-free solutions
containing MPP+ or MPDP were added. The vesicle-
containing fractions were analyzed separately, and MPP+ or
MPDP+ values in the vesicle fractions were integrated.
Erythrocyte uptake assay
Human blood was collected in EDTA (1.6 mg/ml blood)-
containing tubes (Sarstedt S-Monovette, Nuembrecht, Ger-
many) and centrifuged at 200 g for 4 min. The erythrocyte
fraction was resuspended in a buffer containing 21 mM Tris,
4.7 mM KCl, 2 mM CaCl2, 140 mM NaCl, 1.2 mM MgSO4,
and 5.5 mM glucose, pH 7.4. The cells were washed twice with
the buffer by centrifugation at 1000 g for 1 min. The cells were
then treated with MPP+ or MPDP+, as indicated. To assess
intracellular MPP+ levels, the erythrocytes were again washed
by three consecutive centrifugation steps (1000 g, 1 min) to
remove extracellular MPP+ or MPDP+. The erythrocytes were
then lysed by resuspension in H2O for 20 min, supported by
moderate sonication. Proteins were precipitated by the addi-
tion of 0.4 M perchloric acid, and the supernatant was filtered
through a 0.22lm membrane and analyzed by high perfor-
mance liquid chromatography (HPLC).
MPTP conversion in the brain
C57BL/6JRj male mice were kept under 12 h light/12 h
dark cycles at a temperature of 23C and 55% humidity. The
animals had ad libitum access to food and water. All animal
studies were approved by the appropriate institutional gov-
ernmental agency (Regierungspraesidium Tuebingen, Ger-
many) and carried out in an Association for Assessment and
Accreditation of Laboratory Animal Care International-
accredited facility in accordance with the European Con-
vention for Animal Care and Use of Laboratory Animals. The
mice were intraperitoneally injected with MPTP (30 mg/kg;
free base in 0.9% NaCl), cared for over the time intervals
indicated, and then killed by cervical dislocation. The stria-
tum and cerebellum of each mouse were dissected after de-
capitation. The tissues were homogenized in 1 ml of 0.4 M
perchloric acid by sonication. Following a centrifugation step
at 2000 g for 10 min at 4C, the pellet was resuspended in
250 lM of 1 M NaOH. Total protein content was detected by
a BCA assay kit. The supernatant was filtered through a
0.22 lm membrane and analyzed by HPLC.
HPLC analysis
Detection of MPTP, MPP+, and MPDP+ was performed on
a Kontron system (Goebel Analytic, Au/Hallertau, Germany)
comprising a model 520 pump, model 560 autosampler, and
models 535 and 430 diode array detectors set at 245 nm for
MPTP, 295 nm for MPP+, and 345 nm for MPDP+. Samples
were acidified with 9 ll perchloric acid (70%) per ml volume
of sample and centrifuged at 10,000 g for 15 min. The su-
pernatant was filtered through a Chromafil PET-20/15MS
filter with 0.2 lm pore size from Macherey Nagel (Du¨ren,
Germany). Separation was carried out on a C18 nucleosil
column (250· 4.6 mm; 5 lm particle size) from Macherey
Nagel (Du¨ren, Germany) at room temperature. The mobile
phase consisted of acetonitrile: distilled water: triethylamine:
sulfuric acid (12.50: 86.18: 1.04: 0.28, v/v, pH 2.3). The
mobile phase was degassed with an online vacuum degasser
and delivered isocratically at a flow rate of 1 ml/min at an
average pressure of 145 bar. Data analysis was performed
with Geminyx II software (Goebel Analytic). Peak areas of
MPTP, MPDP+, and MPP+ were evaluated with the Geminyx
II software by the application of standard curves obtained for
each of the three individual compounds.
Detection of 13C-labeled intracellular metabolites
For stable isotope labeling, cells were incubated with
[U-13C6] glucose for at least 18 h. To infer relative intracellular
fluxes, intracellular metabolites were extracted and measured
with GC/MS. Cells grown in six-well plates were washed with
1 ml saline solution (0.9%) and quenched with 0.4 ml of cold
(-20C) methanol. After adding an equal volume of cold water,
cells were collected with a cell scraper and transferred in tubes
containing 0.4 ml of cold (-20C) chloroform. The extracts
were shaken at 1400 rpm for 20 min at 4C and centrifuged at
16,000 g for 5 min at 4C; 0.3 ml of the upper aqueous phase
was collected in specific GC glass vials and evaporated under
vacuum at -4C using a refrigerated CentriVap Concentrator
(Labconco). Metabolite derivatization was performed using an
Agilent autosampler. Dried polar metabolites were dissolved in
15ll of 2% methoxyamine hydrochloride in pyridine at 45C.
After 60 min, an equal volume of 2,2,2-trifluoro-N-methyl-N-
trimethylsilyl-acetamide +1% chloro-trimethyl-silane was
added and metabolites were incubated for 30 min at 45C.
GC/MS analysis was performed using an Agilent 6890GC
equipped with a 30 m DB-35MS capillary column. The GC
was connected to an Agilent 5975C MS operating under
electron impact ionization at 70 eV. The MS source was held
at 230C and the quadrupole at 150C. The detector was
operated in scan mode and 1 ll of derivatized sample was
injected in splitless mode. Helium was used as a carrier gas at
a flow rate of 1 ml/min. The GC oven temperature was held at
80C for 6 min and increased to 300C at a rate of 6C/min.
After 10 min, the temperature was increased to 325C at a
rate of 10C/min for 4 min. The run time for each sample was
59 min. For determination of the mass isotopomer distribu-
tion (MID) of citrate, the mass spectrum was corrected for
natural isotope abundance. Data processing from raw spectra
to MID correction and determination was performed using
MetaboliteDetector software (24).
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Abbreviations Used
1,2-MPDP¼ 1-methyl-4-phenyl-1,2-dihydropyridine
DA¼ dopamine
DAT¼ dopamine transporter
DOPC¼ 1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine
DOPE¼ 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine
HRMS¼ high-resolution mass spectrometry
IMA¼ immortalized mouse astrocytes
LUHMES¼ lund human mesencephalic neuron
MAO¼monoamine oxidase
MID¼mass isotopomer distribution
MPDP+¼ 1-methyl-4-phenyl-2,3-dihydropyridinium
MPP+¼ 1-methyl-4-phenyl-pyridinium
MPTP¼ 1-methyl-4-phenyl-tetrahydropyridine
OCT¼ organic cation transporter
PBS¼ phosphate-buffered saline
ROS¼ reactive oxygen species
SD¼ standard deviation
TCA¼ tricarboxylic acid
TFAA¼ trifluoroacetic anhydride
THF¼ tetrahydrofuran
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